{
    "name": "ipilimumab",
    "comment": "Rx",
    "other_names": [
        "Yervoy"
    ],
    "classes": [
        "Antineoplastics",
        "Monoclonal Antibody"
    ],
    "source": "https://reference.medscape.com/drug/yervoy-ipilimumab-999636",
    "pregnancy": {
        "common": [
            "Based on findings from animal studies and its mechanism of action, may cause fetal harm when administered to pregnant females",
            "There is insufficient human data for drug exposure in pregnant females",
            "Advise pregnant females of the potential risk to a fetus",
            "Human IgG1 is known to cross the placental barrier and ipilimumab is an IgG1; therefore, ipilimumab has the potential to be transmitted from the mother to the developing fetus",
            "Verify pregnancy status in females of reproductive potential prior to initiation",
            "Report pregnancies to Bristol-Myers Squibb at 1-844-593-7869"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 3 months following last dose"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Effects of ipilimumab are likely to be greater during second and third trimesters of pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown whether distributed in human breast milk",
            "Advise women to discontinue breastfeeding during treatment and for 3 months after last dose",
            "In monkeys, ipilimumab was present in milk",
            "There are no data to assess the effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe infusion-related reactions can occur; discontinue in patients with severe or life-threatening infusion reactions",
                "Fatal or serious graft-versus-host disease (GVHD) can occur in patients who receive a CTLA-4 receptor blocking antibody either before or after allogeneic hematopoietic stem cell transplantation (HSCT); closely monitor for evidence of GVHD and intervene promptly; consider benefit versus risks of treatment with a CTLA-4 receptor blocking antibody after allogeneic HSCT",
                "May cause fetal harm when administered to pregnant females",
                "When used in combination with nivolumab, refer to nivolumab prescribing information for additional risk information that applies to the combination use treatment"
            ],
            "specific": [
                {
                    "type": "Immune-mediated adverse reactions",
                    "description": [
                        "Owing to the mechanism of action that blocks T-cell inhibitory signal via CTLA-4 pathway, thereby removing inhibition of the immune response to potential immune-mediated adverse reactions",
                        "In general, if interruption or discontinuation is necessary, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less; upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month; consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy",
                        "Therapy can cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis (TEN), and DRESS (drug rash with eosinophilia and systemic symptoms); topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes; withhold or permanently discontinue therapy depending on severity",
                        "Immune-mediated adverse reactions (eg, hepatitis, dermatologic adverse reactions, endocrinopathies, pneumonitis, immune-mediated nephritis with renal dysfunction), which may be severe or fatal, can occur in any organ system or tissue ",
                        "Therapy can cause immune-mediated colitis, which may be fatal; cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; in cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies",
                        "Immune-mediated hypophysitis; hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts; hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated; withhold or permanently discontinue therapy depending on severity",
                        "May occur at any time after initiating therapy",
                        "Immune-mediated adverse reactions usually manifest during treatment, but can also manifest after discontinuation ",
                        "Early detection and management are essential to ensure safe use ",
                        "Monitor for signs and symptoms of underlying immune-mediated adverse reactions",
                        "Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose",
                        "Adrenal insufficiency reported requiring hormone replacement therapy; insufficiency resolved in some patients therapy withheld, some patients received additional treatment after symptom improvement and some had recurrence ",
                        "Institute medical management promptly, including specialty consultation as appropriate",
                        "Ipilimumab administered as single agent or in combination with nivolumab, caused <1% clinically significant immune-mediated adverse reactions, some withfatal outcome, including  ",
                        "Nervous System",
                        "Autoimmune neuropathy (2%), meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-BarrÃ© syndrome, nerve paresis, motor dysfunction",
                        "Cardiovascular",
                        "Angiopathy, myocarditis, pericarditis, temporal arteritis, vasculitis",
                        "Ocular",
                        "Blepharitis, episcleritis, iritis, orbital myositis, scleritis, uveitis. Some cases can be associated with retinal detachment; if uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed in patients receiving this drug and may require treatment with systemic corticosteroids to reduce risk of permanent vision loss",
                        "Gastrointestinal",
                        "Duodenitis, gastritis, pancreatitis",
                        "Musculoskeletal and Connective Tissue",
                        "Arthritis, myositis, polymyalgia rheumatica,polymyositis, rhabdomyolysis",
                        "Other (hematologic/immune)",
                        "Aplastic anemia, conjunctivitis, cytopenias, eosinophilia, erythema multiforme, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), hypersensitivity vasculitis, meningitis, neurosensory hypoacusis, psoriasis, sarcoidosis, systemic inflammatory response syndrome, and solid organ transplant rejection"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "ipilimumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "ipilimumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ipilimumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "ipilimumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "ipilimumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of ipilimumab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, ipilimumab. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "ipilimumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "ipilimumab decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "ipilimumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of ipilimumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and ipilimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and ipilimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and ipilimumab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "ipilimumab, vemurafenib.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Grade 3 increases in transaminases and bilirubin observed in a majority of patients when coadministered."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dermatitis immune",
            "percent": "70"
        },
        {
            "name": "mediated manifestations",
            "percent": "41"
        },
        {
            "name": "up to",
            "percent": "32"
        },
        {
            "name": "Fatigue",
            "percent": "31"
        },
        {
            "name": "Diarrhea",
            "percent": "29"
        },
        {
            "name": "Pruritus",
            "percent": "8"
        },
        {
            "name": "Rash",
            "percent": "7"
        },
        {
            "name": "Colitis",
            "percent": "2"
        },
        {
            "name": "Immune",
            "percent": "1.8"
        },
        {
            "name": "mediated enterocolitis",
            "percent": "1"
        },
        {
            "name": "Immune",
            "percent": null
        },
        {
            "name": "mediated hepatitis",
            "percent": null
        },
        {
            "name": "Endocrinopathies",
            "percent": null
        },
        {
            "name": "including adrenal insufficiency",
            "percent": null
        },
        {
            "name": "hypogonadism",
            "percent": null
        },
        {
            "name": "and hypothyroidism",
            "percent": null
        },
        {
            "name": "Neurologic immune",
            "percent": null
        },
        {
            "name": "mediated manifestations",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "Guillain",
            "percent": null
        },
        {
            "name": "Barre",
            "percent": null
        },
        {
            "name": "peripheral motor neuropathy",
            "percent": null
        },
        {
            "name": "Ocular immune",
            "percent": null
        },
        {
            "name": "mediated manifestations",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "uveitis",
            "percent": null
        },
        {
            "name": "iritis",
            "percent": null
        },
        {
            "name": "Nephrotic immune",
            "percent": null
        },
        {
            "name": "mediated manifestations",
            "percent": null
        },
        {
            "name": "nephritis",
            "percent": null
        },
        {
            "name": "Pulmonary immune",
            "percent": null
        },
        {
            "name": "mediated manifestations",
            "percent": null
        },
        {
            "name": "pneumonitis",
            "percent": null
        },
        {
            "name": "Other immune",
            "percent": null
        },
        {
            "name": "mediated adverse reactions",
            "percent": null
        },
        {
            "name": "include nephritis",
            "percent": null
        },
        {
            "name": "pneumonitis",
            "percent": null
        },
        {
            "name": "meningitis",
            "percent": null
        },
        {
            "name": "pericarditis",
            "percent": null
        },
        {
            "name": "uveitis",
            "percent": null
        },
        {
            "name": "iritis",
            "percent": null
        },
        {
            "name": "and hemolytic anemia",
            "percent": null
        },
        {
            "name": "Meningitis",
            "percent": null
        },
        {
            "name": "Pericarditis",
            "percent": null
        },
        {
            "name": "Myocarditis",
            "percent": null
        },
        {
            "name": "Angiopathy",
            "percent": null
        },
        {
            "name": "Temporal arteritis",
            "percent": null
        },
        {
            "name": "Vasculitis",
            "percent": null
        },
        {
            "name": "Polymyalgia rheumatica",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Blepharitis",
            "percent": null
        },
        {
            "name": "Episcleritis",
            "percent": null
        },
        {
            "name": "Scleritis",
            "percent": null
        },
        {
            "name": "Leukocytoclastic vasculitis",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Psoriasis",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Arthritis",
            "percent": null
        },
        {
            "name": "Autoimmune thyroiditis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS syndrome",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Hemophagocytic lymphohistiocytosis",
            "percent": null
        },
        {
            "name": "HLH",
            "percent": null
        },
        {
            "name": "Immune System",
            "percent": null
        },
        {
            "name": "Graft",
            "percent": null
        },
        {
            "name": "versus",
            "percent": null
        },
        {
            "name": "host disease",
            "percent": null
        },
        {
            "name": "solid organ transplant rejection",
            "percent": null
        }
    ]
}